Mortality (all infants): 0.2 mg IV versus 0.5 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in mortality (all infants): 0.2 mg IV versus 0.5 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
All‐cause mortality (N) Mean hospital stay: 2‐7 days
1 finding from 1 review
All‐cause mortality (N) Mean hospital stay: 2‐7 days
1 finding from 1 review
Mortality [within first 10 weeks after liver transplantation] · adult patients after liver transplantation.
Parenteral nutrition plus branched‐chain‐amino‐acid‐enriched formula showed no clear difference in mortality [within first 10 weeks after liver transplantation] compared with standard isotonic intravenous glucose solution (low certainty).
1 finding from 1 review
Mortality [within first 10 weeks after liver transplantation] · adult patients after liver transplantation.
Standard parenteral nutrition may leads to lower mortality [within first 10 weeks after liver transplantation] compared with standard isotonic intravenous glucose solution (low certainty).
1 finding from 1 review
All‐cause mortality during hospital stay and all‐cause mortality at 1 year · people with endocarditis on the left side of the heart (on native or prosthetic valves) with bacteraemia for Streptococcus, Enterococcus…
It is very uncertain whether partial oral treatment changes all‐cause mortality during hospital stay and all‐cause mortality at… compared with conventional intravenous treatment of endocarditis on the left side… (very low certainty).
1 finding from 1 review
Intervention not reported
Mortality during hospital stay · neonates requiring intubation and ventilation
The intervention showed no clear difference in mortality during hospital stay (moderate certainty).
1 finding from 1 review
Anti‐cytokine, all‐cause mortality ‐ uncertain risk of bias · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies probably leads to lower anti‐cytokines versus placebo, all‐cause mortality compared with placebo (moderate certainty).
3 findings from 1 review
RR 0.92 [0.86, 0.97]
9 studies · 7893 participants
Moderate
RR 0.91 [0.86, 0.97]
7 studies · 7752 participants
Moderate
RR 0.89 [0.8, 1]
4 studies · 2687 participants
Moderate
Anti‐endotoxin ‐ HA‐1A versus placebo, all‐cause mortality · patients with sepsis, severe sepsis, septic shock
It is very uncertain whether monoclonal antibodies changes anti‐endotoxin ‐ HA‐1A versus placebo, all‐cause mortality compared with placebo (very low certainty).
3 findings from 1 review
RR 0.8 [0.54, 1.2]
3 studies · 2668 participants
Very low
RR 1.01 [0.94, 1.09]
6 studies · 4443 participants
Moderate
RR 0.92 [0.79, 1.06]
8 studies · 4676 participants
Low
Anti‐endotoxin E5 versus placebo, all‐ cause mortality · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies showed no clear difference in anti‐endotoxin E5 versus placebo, all‐ cause mortality compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality a. Intervention vs metformin [a. 24 weeks to 4 years] b. Intervention vs thiazolidinediones [b. 24 weeks to 4 years] c. Intervention vs insulin [c. 9 months to 10 years] d. Intervention vs incretin‐based control [d. 52 weeks to... · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies showed no clear difference in anti‐endotoxin, all‐cause mortality ‐ unclear risk of bias compared with placebo (moderate certainty).
1 finding from 1 review
Anti‐endotoxins Anti‐LPS versus placebo, all‐cause mortality · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies showed no clear difference in anti‐endotoxins Anti‐LPS versus placebo, all‐cause mortality compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Mortality during hospitalisation number of infants with event · patients with preventing morbidity and mortality in neonates
The intervention showed no clear difference in mortality during hospitalisation number of infants with event (moderate certainty).
1 finding from 1 review
Anti‐cytokine, all‐cause mortality ‐ low risk of bias studies · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies leads to lower anti‐cytokine, all‐cause mortality ‐ low risk of bias studies compared with placebo (high certainty).
1 finding from 1 review
All‐cause mortality ‐ sensitivity analysis · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies showed no clear difference in anti‐endotoxin, all‐cause mortality ‐ low risk of bias studies compared with placebo (moderate certainty).
1 finding from 1 review
Anticytokine ‐ anti‐TNF‐alpha versus placebo, all‐cause mortality · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies probably leads to lower anticytokine ‐ anti‐TNF‐alpha versus placebo, all‐cause mortality compared with placebo (moderate certainty).
1 finding from 1 review
Overall mortality4 (Subnet based on 71 studies including 21,576 participants) · patients at any age with solid cancer or haematological malignancy
IV or oral iron alone showed no clear difference in overall mortality4 (Subnet based on 71 studies including 21,576… compared with no treatment (low certainty).
1 finding from 1 review
RR 1.5 [0.63, 3.56]
Studies not reported
Low
Overall mortality4 (Subnet based on 71 studies including 21,576 participants) · patients at any age with solid cancer or haematological malignancy
ESA with or without iron showed no clear difference in overall mortality4 (Subnet based on 71 studies including 21,576… compared with no treatment (low certainty).
1 finding from 1 review
RR 1.46 [0.87, 2.43]
Studies not reported
Low
On‐study mortality3 (Subnet based on 55 studies including 15,074 participants) · patients at any age with solid cancer or haematological malignancy
ESA with or without iron showed no clear difference in on‐study mortality3 (Subnet based on 55 studies including 15,074… compared with no treatment (low certainty).
1 finding from 1 review
RR 0.13 [0.01, 2.29]
Studies not reported
Low
On‐study mortality3 (Subnet based on 55 studies including 15,074 participants) · patients at any age with solid cancer or haematological malignancy
IV or oral iron alone showed no clear difference in on‐study mortality3 (Subnet based on 55 studies including 15,074… compared with no treatment (low certainty).
1 finding from 1 review
RR 2.95 [0.71, 12.34]
Studies not reported
Low